login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ABCELLERA BIOLOGICS INC (ABCL) Stock News
USA
- NASDAQ:ABCL -
CA00288U1066
-
Common Stock
5.91
USD
-0.26 (-4.21%)
Last: 10/9/2025, 8:53:27 PM
6.06
USD
+0.15 (+2.54%)
Pre-Market:
10/10/2025, 4:45:55 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ABCL Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: AbCellera Biologics Inc.
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
8 days ago - By: Benzinga
- Mentions:
SPY
ANGO
GIFI
QQQ
...
Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus
8 days ago - By: Benzinga
Why Did AbCellera's Stock Jump Over 7% After Hours?
10 days ago - By: Zacks Investment Research
- Mentions:
AZN
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
11 days ago - By: AbCellera Biologics Inc.
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
11 days ago - By: Zacks Investment Research
AbCellera Biologics Inc. (ABCL) is a Great Momentum Stock: Should You Buy?
a month ago - By: AbCellera Biologics Inc.
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
a month ago - By: AbCellera Biologics Inc.
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
2 months ago - By: AbCellera Biologics Inc.
AbCellera to Participate at Upcoming Investor Conferences in September
2 months ago - By: The Motley Fool
AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript
2 months ago - By: Zacks Investment Research
- Mentions:
XAIR
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates
2 months ago - By: AbCellera Biologics Inc.
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
2 months ago - By: Zacks Investment Research
- Mentions:
MYGN
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates
3 months ago - By: Yahoo Finance
- Mentions:
VZ
PLTR
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
3 months ago - By: Yahoo Finance
Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot
3 months ago - By: AbCellera Biologics Inc.
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
3 months ago - By: Yahoo Finance
Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating
4 months ago - By: Yahoo Finance
- Mentions:
BRKR
AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology
4 months ago - By: Yahoo Finance
- Mentions:
VZ
AAPL
GOOG
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
4 months ago - By: Yahoo Finance
- Mentions:
O
FLS
GTLS
KIM
...
3 Reasons to Buy Realty Income Stock Like There's No Tomorrow
4 months ago - By: Yahoo Finance
- Mentions:
APLS
COMP
REGN
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today
4 months ago - By: The Motley Fool
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today
4 months ago - By: AbCellera Biologics Inc.
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
5 months ago - By: Yahoo Finance
- Mentions:
VZ
UNH
OHI
CSCO
...
Omega Healthcare Investors, Inc. (OHI): A Bull Case Theory
5 months ago - By: Yahoo Finance
- Mentions:
CAPR
CSCO
LRMR
MTCH
...
Capricor Therapeutics, Inc.’s (CAPR): Analysts See 489% Upside Potential
5 months ago - By: Yahoo Finance
- Mentions:
CATX
CSCO
MTCH
COIN
...
Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential
5 months ago - By: Yahoo Finance
- Mentions:
LLY
CSCO
MTCH
COIN
...
AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential
5 months ago - By: Yahoo Finance
- Mentions:
LXRX
PAHC
MMSI
ITGR
...
Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential
5 months ago - By: Yahoo Finance
- Mentions:
ALT
CAPR
CSCO
CATX
...
Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential
5 months ago - By: AbCellera Biologics Inc.
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
5 months ago - By: AbCellera Biologics Inc.
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
5 months ago - By: AbCellera Biologics Inc.
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
5 months ago - By: Zacks Investment Research
- Mentions:
FENC
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
Please enable JavaScript to continue using this application.